| 3 | Opportunities and challenges of implementing Pharmacogenomics in cancer drug development显示文摘Cancer drug development is a time and resources consuming process.Around 90%of drugs entering clinical trials fail due to lack of efficacy and/or safety issues,more often after conspicuous research and economic efforts.Part of the discarded drugs might be beneficial only in a subgroup of the study patients,and some adverse events might be prevented by identifying those patients more vulnerable to toxicities.The implementation of pharmacogenomic biomarkers allows the categorization of patients,to predict efficacy and toxicity and to optimize the drug development process.Around seventy FDA approved drugs currently present one or more genetic biomarker to keep in consideration,and with the progress of Precision Medicine tailoring therapies on individuals’genomic landscape promises to become a new standard of cancer care.In the current article we review the role of pharmacogenomics in cancer drug development,underlying the advantages and challenges of their implementation. | Paolo Tarantino Dario Trapani Stefania Morganti Emanuela Ferraro Giulia Viale Paolo D’Amico Bruno Achutti Duso Giuseppe Curigliano | 2019 | Cancer Drug Resistance2019，2，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员